Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38


Risk indicator taxonomy for supervision of clinical trials on medicinal products.

Jongen PM, van den Bogert CA, van de Laar CW, Notenboom K, Hille ET, Hegger I.

Curr Med Res Opin. 2016 Jul;32(7):1269-76. doi: 10.1185/03007995.2016.1170671. Epub 2016 Apr 21.


Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ.

J Clin Oncol. 2013 Jun 20;31(18):2257-64. doi: 10.1200/JCO.2012.45.3068. Epub 2013 Apr 22.


Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.

van de Water W, Seynaeve C, Bastiaannet E, Markopoulos C, Jones SE, Rea D, Hasenburg A, Putter H, Hille ET, Paridaens R, de Craen AJ, Westendorp RG, van de Velde CJ, Liefers GJ.

Oncologist. 2013;18(1):8-13. doi: 10.1634/theoncologist.2012-0315. Epub 2012 Dec 20.


Costs of different follow-up strategies in early breast cancer: a review of the literature.

van Hezewijk M, van den Akker ME, van de Velde CJ, Scholten AN, Hille ET.

Breast. 2012 Dec;21(6):693-700. doi: 10.1016/j.breast.2012.09.009. Epub 2012 Oct 22. Review.


Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.

van de Water W, Fontein DB, van Nes JG, Bartlett JM, Hille ET, Putter H, Robson T, Liefers GJ, Roumen RM, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JW, van de Velde CJ.

Eur J Cancer. 2013 Jan;49(2):297-304. doi: 10.1016/j.ejca.2012.07.026. Epub 2012 Sep 3.


Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.

Fontein DB, Houtsma D, Hille ET, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, Guchelaar HJ, Gelderblom H, Dirix LY, Paridaens R, Bartlett JM, Nortier JW, van de Velde CJ; Dutch TEAM Steering Committee.

Ann Oncol. 2012 Dec;23(12):3091-7. doi: 10.1093/annonc/mds204. Epub 2012 Aug 2.


Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.

van Nes JG, Fontein DB, Hille ET, Voskuil DW, van Leeuwen FE, de Haes JC, Putter H, Seynaeve C, Nortier JW, van de Velde CJ.

Breast Cancer Res Treat. 2012 Jul;134(1):267-76. doi: 10.1007/s10549-012-2028-2. Epub 2012 Mar 28.


Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

van de Water W, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE.

JAMA. 2012 Feb 8;307(6):590-7. doi: 10.1001/jama.2012.84.


Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.

van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Kranenbarg EM, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG, Liefers GJ, van de Velde CJ.

Oncologist. 2012;17(1):55-63. doi: 10.1634/theoncologist.2011-0037. Epub 2011 Dec 30.


Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.

Bartlett JM, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ET, Kay C, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix L, Seynaeve C, Rea D.

J Clin Oncol. 2011 Apr 20;29(12):1531-8. doi: 10.1200/JCO.2010.30.3677. Epub 2011 Mar 21.


Professionals' opinion on follow-up in breast cancer patients; perceived purpose and influence of patients' risk factors.

van Hezewijk M, Hille ET, Scholten AN, Marijnen CA, Stiggelbout AM, van de Velde CJ.

Eur J Surg Oncol. 2011 Mar;37(3):217-24. doi: 10.1016/j.ejso.2011.01.001. Epub 2011 Jan 26.


Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE.

Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4.


Tailored follow-up for early breast cancer patients: a prognostic index that predicts locoregional recurrence.

van Nes JG, Putter H, van Hezewijk M, Hille ET, Bartelink H, Collette L, van de Velde CJ; EORTC Breast Cancer Group.

Eur J Surg Oncol. 2010 Jul;36(7):617-24. doi: 10.1016/j.ejso.2010.05.010. Epub 2010 Jun 16.


Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.

van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ; Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trialists, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW.

Br J Surg. 2010 May;97(5):671-9. doi: 10.1002/bjs.6962.


Intelligence of very preterm or very low birthweight infants in young adulthood.

Weisglas-Kuperus N, Hille ET, Duivenvoorden HJ, Finken MJ, Wit JM, van Buuren S, van Goudoever JB, Verloove-Vanhorick SP; Dutch POPS-19 Collaborative Study Group.

Arch Dis Child Fetal Neonatal Ed. 2009 May;94(3):F196-200. doi: 10.1136/adc.2007.135095. Epub 2008 Sep 19.


Social lifestyle, risk-taking behavior, and psychopathology in young adults born very preterm or with a very low birthweight.

Hille ET, Dorrepaal C, Perenboom R, Gravenhorst JB, Brand R, Verloove-Vanhorick SP; Dutch POPS-19 Collaborative Study Group.

J Pediatr. 2008 Jun;152(6):793-800, 800.e1-4. doi: 10.1016/j.jpeds.2007.11.041. Epub 2008 Feb 4.


Functional outcomes and participation in young adulthood for very preterm and very low birth weight infants: the Dutch Project on Preterm and Small for Gestational Age Infants at 19 years of age.

Hille ET, Weisglas-Kuperus N, van Goudoever JB, Jacobusse GW, Ens-Dokkum MH, de Groot L, Wit JM, Geven WB, Kok JH, de Kleine MJ, Kollée LA, Mulder AL, van Straaten HL, de Vries LS, van Weissenbruch MM, Verloove-Vanhorick SP; Dutch Collaborative POPS 19 Study Group.

Pediatrics. 2007 Sep;120(3):e587-95.


Prevalence and independent risk factors for hearing loss in NICU infants.

Hille ET, van Straaten HI, Verkerk PH; Dutch NICU Neonatal Hearing Screening Working Group.

Acta Paediatr. 2007 Aug;96(8):1155-8.


Lipid profile and carotid intima-media thickness in a prospective cohort of very preterm subjects at age 19 years: effects of early growth and current body composition.

Finken MJ, Inderson A, Van Montfoort N, Keijzer-Veen MG, van Weert AW, Carfil N, Frölich M, Hille ET, Romijn JA, Dekker FW, Wit JM; Dutch POPS-19 Collaborative Study Group.

Pediatr Res. 2006 Apr;59(4 Pt 1):604-9.


Preterm birth and later insulin resistance: effects of birth weight and postnatal growth in a population based longitudinal study from birth into adult life.

Finken MJ, Keijzer-Veen MG, Dekker FW, Frölich M, Hille ET, Romijn JA, Wit JM; Dutch POPS-19 Collaborative Study Group.

Diabetologia. 2006 Mar;49(3):478-85. Epub 2006 Feb 1.


Nonresponse bias in a follow-up study of 19-year-old adolescents born as preterm infants.

Hille ET, Elbertse L, Gravenhorst JB, Brand R, Verloove-Vanhorick SP; Dutch POPS-19 Collaborative Study Group.

Pediatrics. 2005 Nov;116(5):e662-6.


Is attrition bias a problem in neonatal follow-up?

Hille ET, den Ouden AL, Stuifbergen MC, Verrips GH, Vogels AG, Brand R, Gravenhorst JB, Verloove-Vanhorick SP.

Early Hum Dev. 2005 Nov;81(11):901-8. Epub 2005 Sep 16.


Is blood pressure increased 19 years after intrauterine growth restriction and preterm birth? A prospective follow-up study in The Netherlands.

Keijzer-Veen MG, Finken MJ, Nauta J, Dekker FW, Hille ET, Frölich M, Wit JM, van der Heijden AJ; Dutch POPS-19 Collaborative Study Group.

Pediatrics. 2005 Sep;116(3):725-31.


Catch-up growth up to ten years of age in children born very preterm or with very low birth weight.

Knops NB, Sneeuw KC, Brand R, Hille ET, den Ouden AL, Wit JM, Verloove-Vanhorick SP.

BMC Pediatr. 2005 Jul 20;5:26.


Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation.

Keijzer-Veen MG, Schrevel M, Finken MJ, Dekker FW, Nauta J, Hille ET, Frölich M, van der Heijden BJ; Dutch POPS-19 Collaborative Study Group.

J Am Soc Nephrol. 2005 Sep;16(9):2762-8. Epub 2005 Jun 29.


Associations between prenatal and infancy weight gain and BMI, fat mass, and fat distribution in young adulthood: a prospective cohort study in males and females born very preterm.

Euser AM, Finken MJ, Keijzer-Veen MG, Hille ET, Wit JM, Dekker FW; Dutch POPS-19 Collaborative Study Group.

Am J Clin Nutr. 2005 Feb;81(2):480-7.


Preeclampsia and its interaction with common variants in thrombophilia genes.

De Maat MP, Jansen MW, Hille ET, Vos HL, Bloemenkamp KW, Buitendijk S, Helmerhorst FM, Wladimiroff JW, Bertina RM, De Groot CJ.

J Thromb Haemost. 2004 Sep;2(9):1588-93.


Bilateral hearing impairment in Dutch neonatal intensive care unit infants with unilateral failure on hearing screening.

Hille ET, Verkerk PH, van Straaten HL.

Pediatrics. 2004 May;113(5):1467-8. No abstract available.


Implementation of a nation-wide automated auditory brainstem response hearing screening programme in neonatal intensive care units.

van Straaten HL, Hille ET, Kok JH, Verkerk PH; Dutch NICU Neonatal Hearing Screening Working Group.

Acta Paediatr. 2003;92(3):332-8.


Behavioural problems in children who weigh 1000 g or less at birth in four countries.

Hille ET, den Ouden AL, Saigal S, Wolke D, Lambert M, Whitaker A, Pinto-Martin JA, Hoult L, Meyer R, Feldman JF, Verloove-Vanhorick SP, Paneth N.

Lancet. 2001 May 26;357(9269):1641-3.


Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).

Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W.

Int J Cancer. 2000 Sep 15;87(6):809-11.


Two centuries of mortality in ten large families with Huntington disease: a rising impact of gene carriership.

Hille ET, Siesling S, Vegter-van der Vlis M, Vandenbroucke JP, Roos RA, Rosendaal FR.

Epidemiology. 1999 Nov;10(6):706-10.


A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families.

van der Velden PA, Sandkuijl LA, Bergman W, Hille ET, Frants RR, Gruis NA.

Genome Res. 1999 Jun;9(6):575-80.


Risk of cutaneous malignant melanoma in patients with nonfamilial atypical nevi from a pigmented lesions clinic.

Snels DG, Hille ET, Gruis NA, Bergman W.

J Am Acad Dermatol. 1999 May;40(5 Pt 1):686-93.


Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994.

Hille ET, van Duijn E, Gruis NA, Rosendaal FR, Bergman W, Vandenbroucke JP.

J Invest Dermatol. 1998 May;110(5):788-92.


Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C).

Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR.

Blood. 1997 Mar 15;89(6):1963-7.


School performance in very preterm children.

Lya den Ouden A, Hille ET, Bauer L, Verloove-Vanhorick SP.

Lancet. 1993 Aug 28;342(8870):550-1. No abstract available.


Supplemental Content

Loading ...
Support Center